444344-91-6

Usage

Uses

Used in Pharmaceutical Industry:
4-(Benzyloxycarbonylamino)bicyclo[2.2.2]octane-1-carboxylic acid is used as a building block for the synthesis of pharmaceutical compounds due to its unique structure and functional groups. Its potential applications in drug development may include the creation of novel therapeutic agents or the modification of existing drugs to enhance their efficacy, selectivity, or stability.
Used in Organic Synthesis:
In the field of organic synthesis, 4-(Benzyloxycarbonylamino)bicyclo[2.2.2]octane-1-carboxylic acid serves as a versatile intermediate or reagent for the preparation of various organic compounds. Its structural features and functional groups can be utilized in a range of chemical reactions, enabling the synthesis of complex molecules with specific properties and applications.
Used in Research and Development:
4-(Benzyloxycarbonylamino)bicyclo[2.2.2]octane-1-carboxylic acid is employed as a research compound to study its properties, reactivity, and potential applications. Scientists and researchers may use 4-(BenzyloxycarbonylaMino)bicyclo[2.2.2]octane-1-carboxyli- -cacid to explore new chemical reactions, investigate its interactions with other molecules, or develop new methods for its synthesis and modification. This research can contribute to the advancement of chemical knowledge and the discovery of new applications for this unique compound.

Upstream product

• 834-50-4 4-(ethoxycarbonyl)bicyclo[2.2.2]octane-1-carboxylic acid 
• 18720-35-9 bicyclo[2.2.2]octane-1,4-dicarboxylic acid monomethyl ester 
• 100-51-6 benzyl alcohol 
• 862501-91-5 methyl 4-(((benzyloxy)carbonyl)amino)bicyclo[2.2.2]octane-1-carboxylate 
• 444344-90-5 ethyl 4-[[(benzyloxy)carbonyl]amino]-bicyclo[2.2.2]octane-1-carboxylate 

Downstream Products

• 444344-92-7 N-[4-[[(benzyloxy)carbonyl]amino]bicyclo[2.2.2]octane-1-carbonyl]-L-glutamic acid dimethyl ester 
• 862501-97-1 2-tetrahydropyranyl 4-benzyloxycarbonylamino bicyclo[2.2.2]octane-1-carboxylate 
• 863303-83-7 4-benzyloxycarbonylaminobicyclo[2.2.2]octane-1-carboxamide 
• 864063-55-8 benzyl (4-(hydroxymethyl)bicyclo[2.2,2]octan-1-yl)carbamate 
• 444344-90-5 ethyl 4-[[(benzyloxy)carbonyl]amino]-bicyclo[2.2.2]octane-1-carboxylate 
• 1245643-16-6 4-(difluoromethyl)bicyclo[2.2.2]octan-1-amine 

Relevant academic research and scientific papers

CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with EGFR and/or HER2 activity.

NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF

The present invention relates to inhibitors of 11-β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

BICYCLIC AMIDE DERIVATIVES

Novel bicycloamide derivatives (general formula (1)) and pharmaceutically acceptable salts thereof effectively inhibit DPP-IV. The bicycloamide derivatives are represented by the general formula (1): Pharmaceutically acceptable salts thereof are also included (Example: (2S,4S)-1-[[(4-carbamoylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)).

BICYCLO DERIVATIVE

A novel bicyclo derivative represented by the following general formula (1), or a pharmaceutically acceptable salt thereof, acts as an effective DPP-IV inhibitor: One example is (2S,4S)-1-[[N-(4-methylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidi

BICYCLOESTER DERIVATIVE

SUMMARY Novel bicycloester derivatives and pharmaceutically acceptable salts thereof have high DPP-IV inhibitory activity. SOLVING MEANS The novel bicycloester derivatives are represented by the general formula (1): Pharmaceutically acceptable salts there

Synthesis and antifolate evaluation of the aminopterin analogue with a bicyclo[2.2.2]octane ring in place of the benzene ring

N-[4-[[2,4-diamino-6-pteridinyl)methyl]amino]bicyclo[2.2.2]octane-1- carbonyl]-L-glutamic acid (1) was synthesized and tested for antifolate activity. N-(4-Aminobicyclo[2.2.2]octane-1-carbonyl-L-glutamic acid dimethyl ester (6), the side chain precursor to subject compound 1, was synthesized readily via reported bicyclo[2.2.2]octane-1,4-dicarboxylic acid monoethyl ester (2). The side chain precursor 6 was alkylated by 6-(bromomethyl)-2,4-pteridinediamine (7). Subsequent ester hydrolysis then afforded 1. Antifolate and antitumor evaluation of 1 verses L1210 dihydrofolate reductase (DHFR) and three tumor cell lines (L1210, S180, and HL60) showed it to be ineffective. Although compound 1 was very similar to aminopterin structurally, the bicyclo[2.2.2]octane ring system in place of the phenyl ring in the p-aminobenzoate moiety effectively negates the stoichiometric binding displayed by many classical DHFR inhibitors bearing appropriate aromatic ring systems in the side chain.